When Sanofi won FDA approval in July 2026 for the first anticancer treatment administered with an on-body injector (OBI), the Enable Injections enFuse platform made it possible. The enFuse OBI secured its initial combination product FDA approval in 2023 for adults with paroxysmal nocturnal hemoglobinuria, a rare blood disorder. That milestone made enFuse the “first…
The post Inside the first-of-its-kind Enable Injections enFuse drug delivery wearable appeared first on Medical Design and Outsourcing.